StreetInsider.com News Articles

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 23 Oct 2026 16:15:00 -0400

SAN FRANCISCO, Oct. 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on October 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 45,750 shares of its common stock and 2,775 restricted stock units (RSUs) to sixteen newly-hired employees under Nektar's 2025 Inducement Plan, as amended.

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 23 Oct 2026 16:15:00 -0400

Form S-8 NEKTAR THERAPEUTICS

Tue, 20 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261020/27205842.html

Leerink Starts Nektar Therapeutics (NKTR) at Outperform

Mon, 12 Oct 2026 06:12:11 -0400

Leerink initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Outperform rating and a price target of $130.00.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $41.17 yesterday.

UBS Starts Nektar Therapeutics (NKTR) at Neutral

Mon, 12 Oct 2026 02:21:15 -0400

UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of $53.00.

The analyst comments: “We initiate coverage of Nektar Therapeutics (NKTR) with a Neutral rating and a $53 PT. NKTR is the leader in the regulatory T cell (Treg) space, a promising immunology approach with broad potential across immune diseases. Its lead asset, rezpegaldesleukin (Rezpeg), has generated positive Phase 2b proof-of-concept data in both atopic dermatitis (AD) and alopecia areata (AA). We see a meaningful commercial opportunity in both indications, assuming Phase 3 success. Beyond Rezpeg, NKTR's preclinical TNFR2 agonist is

UBS Starts Nektar Therapeutics (NKTR) at Neutral

Mon, 12 Oct 2026 02:21:15 -0400

UBS analyst Alice Nettleton initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of $53.00.

Raymond James Starts Nektar Therapeutics (NKTR) at Market Perform

Thu, 08 Oct 2026 16:07:14 -0400

(Updated - October 8, 2026 4:07 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Market Perform rating.

The analyst comments "We are initiating coverage of Nektar Therapeutics (NKTR) with a Market Perform rating. Nektar is developing novel therapies for autoimmune conditions, with a focus on regulatory T-cell (Treg) biology. Lead asset rezpegaldesleukin (rezpeg) is an IL-2 Treg stimulator in late-phase development for atopic dermatitis (AD) and alopecia areata (AA)."

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar

Raymond James Starts Nektar Therapeutics (NKTR) at Market Perform

Thu, 08 Oct 2026 16:07:14 -0400

(Updated - October 8, 2026 4:07 PM EDT)

Raymond James analyst Thomas Deal initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Market Perform rating.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar

Citi reiterates buy rating on Nektar Therapeutics with $151 target

Mon, 05 Oct 2026 06:57:26 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $151.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

Nektar shares closed at $43.58, reflecting a roughly 60% decline from year-to-date highs reached in April 2026 following positive Phase 2 52-week alopecia areata data. The analyst noted the decline occurred despite no negative news affecting the clinical or commercial outlook for the company's drug candidate rezpeg in atopic dermatitis or alopecia areata.

Semenkow noted that Nektar shares are trading at an enterprise value of approximately $800 million, which she said trails peers primarily valued on atopic dermatitis, including Kymera Therapeutics (NASDAQ: KYMR) at $8.8

Citi reiterates buy rating on Nektar Therapeutics with $151 target

Mon, 05 Oct 2026 06:57:26 -0400

Citi analyst Samantha Semenkow reiterated a Buy rating and $151.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)

Fri, 02 Oct 2026 06:56:59 -0400

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $185.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

The analyst commented: "On October 1, Nektar presented 52-week treatment and six-month off-treatment data from the Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata (AA) at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna and hosted a conference call to review the data. Of the eight patients who achieved SALT ≤20 after 52 weeks of rezpeg treatment, 75% (6/8) maintained the response at four months and 63% (5/8) at six months off treatment (NRI, with all patients available for

Form 8-K NEKTAR THERAPEUTICS For: Oct 01

Thu, 01 Oct 2026 07:58:00 -0400

si-local-file:///var/storage/secattach/20261001/27131678.html

Nektar drug shows durability in skin disease trials at EADV 2026

Thu, 01 Oct 2026 07:34:57 -0400

Nektar Therapeutics (Nasdaq: NKTR) presented Phase 2b data on its investigational drug rezpegaldesleukin at the European Academy of Dermatology and Venereology Congress in Vienna, Austria on Oct. 1, 2026, covering results from two dermatological studies.

In the REZOLVE-AA study of patients with severe-to-very-severe alopecia areata, 75% of patients who completed 52 weeks of treatment maintained a SALT Score of 20 or below after four months off treatment, and 63% maintained that response after six months off treatment. The proportion of patients achieving a SALT Score of 10 or below rose from 7% at the end of the 52-week treatment period to

Nektar drug shows durability in skin disease trials at EADV 2026

Thu, 01 Oct 2026 07:34:57 -0400

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Thu, 01 Oct 2026 07:30:00 -0400

Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism

In alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six months off treatment

Hair regrowth continued for 6 months off treatment with

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026

Thu, 01 Oct 2026 07:30:00 -0400

Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism

In alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six months off treatment

Hair regrowth continued for 6 months off treatment with

Nektar presents early biomarker data for eczema drug at EADV 2026

Wed, 30 Sep 2026 10:31:54 -0400

Nektar Therapeutics (Nasdaq: NKTR) and researchers at the Icahn School of Medicine at Mount Sinai presented biomarker data from a sub-study of the Phase 2b REZOLVE-AD trial at the European Academy of Dermatology and Venereology Congress in Vienna, Austria on Sept. 30, 2026.
The multi-omic sub-study analyzed blood and lesional skin tape samples from 100 patients during a 16-week induction period, including 59 patients treated with rezpegaldesleukin at 24 µg/kg every two weeks and 41 patients who received placebo. The analysis examined gene and protein expression in skin and serum during the first weeks of treatment to assess whether early molecular

Nektar presents early biomarker data for eczema drug at EADV 2026

Wed, 30 Sep 2026 10:31:54 -0400

Nektar Therapeutics (Nasdaq: NKTR) and researchers at the Icahn School of Medicine at Mount Sinai presented biomarker data from a sub-study of the Phase 2b REZOLVE-AD trial at the European Academy of Dermatology and Venereology Congress in Vienna, Austria on Sept. 30, 2026.
The multi-omic sub-study analyzed blood and lesional skin tape samples from 100 patients during a 16-week induction period, including 59 patients treated with rezpegaldesleukin at 24 µg/kg every two weeks and 41 patients who received placebo. The analysis examined gene and protein expression in skin and serum during the first weeks of treatment to assess whether early molecular

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients

Wed, 30 Sep 2026 10:30:00 -0400

Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response

SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients

Wed, 30 Sep 2026 10:30:00 -0400

Rezpegaldesleukin-associated improvements were detected as early as Week 2 and were significantly correlated with subsequent clinical response

SAN FRANCISCO and VIENNA, Sept. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing

Nektar to present rezpegaldesleukin data at EADV Congress 2026

Mon, 28 Sep 2026 08:02:02 -0400

Nektar Therapeutics (Nasdaq: NKTR) announced three oral presentations of data from its Phase 2b studies of rezpegaldesleukin at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place September 30 through October 3 in Vienna, Austria.
The presentations include new data from the REZOLVE-AA study in patients with alopecia areata, featuring 6-month off-treatment findings measuring durability of response using the Severity of Alopecia Tool (SALT). The 92-patient study enrolled patients with severe-to-very-severe alopecia areata who had not previously been treated with a JAK inhibitor or other biologic.
A second oral presentation will cover maintenance data from the REZOLVE-AD study, a

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Mon, 28 Sep 2026 08:00:00 -0400

New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata

Company to host conference call with investors and analysts on October 1, 2026 at 8:00 AM ET/2:00 PM CET

SAN FRANCISCO, Sept. 28, 2026 /PRNewswire/

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Mon, 28 Sep 2026 08:00:00 -0400

New data to be presented from the REZOLVE-AA study at EADV, including 6-month off-treatment data for patients with severe-to-very-severe alopecia areata

Company to host conference call with investors and analysts on October 1, 2026 at 8:00 AM ET/2:00 PM CET

SAN FRANCISCO, Sept. 28, 2026 /PRNewswire/

Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: Two Seas Capital LP

Mon, 28 Sep 2026 07:51:00 -0400
si-local-file:///var/storage/secattach/20260928/27110152.html

Form 4 NEKTAR THERAPEUTICS For: Sep 23 Filed by: WHITFIELD ROY A

Fri, 25 Sep 2026 20:29:00 -0400
si-local-file:///var/storage/secattach/20260925/27108445.html